{
  "clinical_guidelines": [
    {
      "guideline_title": "2023 AHA/ACC/HFSA Heart Failure Management Guideline",
      "organization": "American Heart Association, American College of Cardiology, Heart Failure Society of America",
      "publication_year": 2023,
      "version": "2023 Update",
      "scope": "Comprehensive management of heart failure in adults",
      "key_recommendations": [
        {
          "class": "Class I",
          "level": "Level A",
          "recommendation": "ACE inhibitors or ARBs are recommended for all patients with heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality",
          "evidence_summary": "Multiple large randomized trials demonstrate consistent benefit"
        },
        {
          "class": "Class I",
          "level": "Level A", 
          "recommendation": "Beta-blockers are recommended for all stable patients with HFrEF to reduce mortality and hospitalization",
          "evidence_summary": "Meta-analysis of major trials shows 35% reduction in mortality"
        },
        {
          "class": "Class IIa",
          "level": "Level B",
          "recommendation": "SGLT2 inhibitors are reasonable for patients with HFrEF to reduce cardiovascular death and heart failure hospitalization",
          "evidence_summary": "Recent trials show benefit regardless of diabetes status"
        }
      ],
      "diagnostic_criteria": {
        "hfref": "Left ventricular ejection fraction ≤40%",
        "hfmref": "Left ventricular ejection fraction 41-49%",
        "hfpef": "Left ventricular ejection fraction ≥50%"
      },
      "treatment_algorithm": "Guideline-directed medical therapy should be initiated and optimized before considering device therapy or advanced heart failure treatments"
    },
    {
      "guideline_title": "American Diabetes Association Standards of Medical Care in Diabetes - 2023",
      "organization": "American Diabetes Association",
      "publication_year": 2023,
      "version": "2023 Standards",
      "scope": "Comprehensive diabetes care including prevention, diagnosis, and management",
      "key_recommendations": [
        {
          "class": "Strong Recommendation",
          "level": "Grade A",
          "recommendation": "HbA1c target <7% for most adults with diabetes",
          "evidence_summary": "Reduces microvascular complications and long-term macrovascular events"
        },
        {
          "class": "Strong Recommendation", 
          "level": "Grade A",
          "recommendation": "Metformin is the preferred initial pharmacologic agent for type 2 diabetes",
          "evidence_summary": "Proven efficacy, safety profile, and cardiovascular benefits"
        },
        {
          "class": "Conditional Recommendation",
          "level": "Grade B",
          "recommendation": "Consider GLP-1 receptor agonists or SGLT2 inhibitors for patients with established cardiovascular disease",
          "evidence_summary": "Cardiovascular outcome trials demonstrate reduced MACE"
        }
      ],
      "diagnostic_criteria": {
        "diabetes": "HbA1c ≥6.5% or fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL",
        "prediabetes": "HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL"
      },
      "screening_recommendations": "Screen all adults ≥35 years for diabetes/prediabetes every 3 years"
    },
    {
      "guideline_title": "ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease",
      "organization": "American College of Cardiology, American Heart Association",
      "publication_year": 2023,
      "version": "2023 Update",
      "scope": "Primary prevention of atherosclerotic cardiovascular disease in adults",
      "key_recommendations": [
        {
          "class": "Class I",
          "level": "Level A",
          "recommendation": "Lifestyle modification is the foundation of cardiovascular disease prevention",
          "evidence_summary": "Comprehensive evidence supports diet, exercise, and smoking cessation"
        },
        {
          "class": "Class I",
          "level": "Level A",
          "recommendation": "Statin therapy for adults 40-75 years with LDL-C ≥70 mg/dL and 10-year ASCVD risk ≥7.5%",
          "evidence_summary": "Multiple primary prevention trials demonstrate mortality benefit"
        },
        {
          "class": "Class IIa",
          "level": "Level B-R",
          "recommendation": "Consider coronary artery calcium scoring for risk assessment in intermediate-risk patients",
          "evidence_summary": "Improves risk stratification and treatment decisions"
        }
      ],
      "risk_assessment": "Use Pooled Cohort Equations to estimate 10-year ASCVD risk",
      "treatment_thresholds": "Consider statin therapy when 10-year ASCVD risk ≥7.5% in patients 40-75 years"
    }
  ]
}